CLINICAL TRIAL: NSABP P-2: STAR

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 在P-1研究中，他莫昔芬被证明可以预防浸润性和原位乳腺癌的发展。雷洛昔芬已被证明是预防骨质疏松症的有效药物。在雷洛昔芬评估(MORE)试验的多项结果中观察到，与对照组相比，服用雷洛昔芬的患者组乳腺癌较少。这项研究将确定雷洛昔芬在降低绝经后乳腺癌风险增加的绝经后妇女的浸润性乳腺癌发病率方面是否比他莫昔芬更有效。第二个目标是确定雷洛昔芬与他莫昔芬相比是否降低子宫内膜癌的发生率。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In the P-1 study, tamoxifen was shown to prevent the development of invasive and in situ breast cancer. Raloxifene has shown to be an effective drug for the prevention of osteoporosis. It was observed in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial that there were fewer breast cancers in the group of patients that had taken raloxifene compared to the controls. This study will determine if raloxifene is either more or less effective than tamoxifen in reducing the incidence of invasive breast cancer in postmenopausal women who are at increased risk for the disease. A secondary goal is to determine whether raloxifene reduces the endometrial cancer rate compared to tamoxifen.